Gsk (LSE:GSK)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMGSK

RNS Number : 3649H

GlaxoSmithKline PLC

13 March 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

13 March 2015, London UK - LSE announcement

GSK completes partial sale of Aspen Pharmacare Holdings Ltd shares

Further to the announcement by GSK on 12 March 2015, GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 372 per share (the "Placing Shares"), raising gross proceeds of approximately ZAR 10.5 billion.

Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital. GSK has undertaken not to dispose of any further shares in Aspen for a period of 180 days following completion, subject to certain limited exceptions.

The gross proceeds of thetransaction are equivalent to GBP 574 million at the prevailing exchange rate on 12 March 2015. Proceeds from the transaction will be used for general corporate purposes. The net profit on disposal will not be included in core operating profit and core EPS in 2015 and it is expected that GSK will no longer account for Aspen as an associate going forward.

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 
 GSK enquiries: 
 UK Media enquiries:   David Mawdsley      +44 (0) 20 8047   (London) 
                                            5502 
                       Simon Steel         +44 (0) 20 8047   (London) 
                                            5502 
                       David Daley         +44 (0) 20 8047   (London) 
                                            5502 
                       Catherine Hartley   +44 (0) 20 8047   (London) 
                                            5502 
                       Sarah Spencer       +44 (0) 20 8047   (London) 
                                            5502 
                       Claire Brough       +44 (0) 20 8047   (London) 
                                            5502 
 
 Analyst/Investor      Ziba Shamsi         +44 (0) 20 8047   (London) 
  enquiries:                                5543 
                       Gary Davies         +44 (0) 20 8047   (London) 
                                            5503 
                       James Dodwell       +44 (0) 20 8047   (London) 
                                            2406 
 
 
 Cautionary statement regarding forward-looking statements 
  This announcement does not constitute a prospectus or an offer 
  or invitation to purchase securities. 
  This announcement is only addressed to, and directed at, persons 
  in member states of the European Economic Area ("EEA") who are 
  "qualified investors" within the meaning of Article 2(1)(e) 
  of the Prospectus Directive (Directive 2003/71/EC) as amended 
  by the 2010 PD Amending Directive (Directive 2010/73/EU), as 
  and to the extent implemented in the relevant EEA member state, 
  and any relevant implementing measure in the relevant member 
  state. 
  In addition, in the United Kingdom, this announcement is not 
  being distributed, nor has it been approved for the purposes 
  of Section 21 of the Financial Services and Markets Act 2000 
  ("FSMA"), by a person authorised under FSMA and is directed 
  only at persons (i) who are persons having professional experience 
  in matters relating to investments who fall within the definition 
  of "investment professionals" in Article 19(5) of the Financial 
  Services and Markets Act 2000 (Financial Promotion) Order 2005, 
  as amended (the "Order"), or (ii) persons who are high net worth 
  entities falling within Article 49(2)(a) to (d) of the Order, 
  or (iii) other persons to whom it may lawfully be communicated 
  ("relevant persons"). Under no circumstances should persons 
  who are not relevant persons rely or act upon the contents of 
  this announcement. Any investment or investment activity to 
  which this announcement relates in the United Kingdom is available 
  only to, and will be engaged only with, relevant persons. 
  This announcement is not an offer for sale of securities in 
  the United States. Securities may not be offered or sold in 
  the United States absent registration with the United States 
  Securities and Exchange Commission or an exemption from registration 
  under the U.S. Securities Act of 1933, as amended. GSK does 
  not intend to register any part of the offering in the United 
  States or to conduct a public offering in the United States 
  of the shares to which this announcement relates. 
  The Offering and the distribution of this announcement do not, 
  nor are they intended to, constitute an offer for the sale of 
  or subscription for, or the solicitation of an offer to buy 
  and subscribe for, shares to the public as defined in the South 
  African Companies Act, No 71 of 2008 (as amended or otherwise) 
  (the "South African Act") and will not be distributed to any 
  person in South Africa in any manner which could be construed 
  as an offer to the public in terms of the South African Act. 
  The Offering and the distribution of this announcement do not, 
  nor are they intended to, constitute a prospectus prepared and 
  registered under the South African Act. 
  The Offering and the distribution of this announcement and other 
  information in connection with the Offering in certain jurisdictions 
  may be restricted by law. No action has been taken that would 
  permit the Offering or distribution of this announcement in 
  any jurisdiction where action for such purpose is required. 
  Persons into whose possession any document or other information 
  referred to herein comes should inform themselves about and 
  observe any such restriction. Any failure to comply with these 
  restrictions may constitute a violation of the securities laws 
  of any such jurisdiction. 
  Citigroup Global Markets Limited and UBS Limited, which are 
  authorised and regulated by the Financial Conduct Authority, 
  are acting for GSK and for no one else in connection with the 
  Offering and will not be responsible to anyone other than GSK 
  for providing the protections afforded to their customers or 
  for affording advice in relation to the Offering, the contents 
  of this announcement or any transaction, arrangement or other 
  matter referred to in this announcement. Citigroup Global Markets 
  Limited and UBS Limited may participate in the Offering on a 
  proprietary basis. 
  This announcement does not represent the announcement of a definitive 
  agreement to proceed with the Offering and, accordingly, there 
  can be no certainty that the Offering will proceed. GSK reserves 
  the right not to proceed with the Offering or to vary the terms 
  of the Offering in any way. 
  GSK cautions investors that any forward-looking statements or 
  projections made by GSK, including those made in this announcement, 
  are subject to risks and uncertainties that may cause actual 
  results to differ materially from those projected. Such factors 
  include, but are not limited to, those described in Item 3.D 
  "Risk factors" in GSK's Annual Report on Form 20-F for 2014. 
 
 
 Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLIFIRVIIVLIE